[
  {
    "step_by_step_thinking": "The patient presents with symptoms of anemia, splenomegaly, and bone marrow fibrosis, along with a positive JAK2 mutation. These findings are consistent with primary myelofibrosis (PMF). Ruxolitinib, a JAK1/JAK2 inhibitor, is the first-line therapy for symptomatic PMF, particularly in intermediate or high-risk cases. Cladribine is used for hairy cell leukemia, Prednisone for autoimmune conditions, and Imatinib for CML or Ph+ leukemias. The most appropriate next step is Ruxolitinib.",
    "answer_choice": "D"
  }
]